Replies to post #644 on Vascular Biogenics Ltd (VBLT)

[davidal66]

Right, and if they receive a single Avastin infusion and drop out, they are then included in the survival analysis. If they receive a single VB-111 infusion, they are included in the analysis. The trial had planned to enroll 252 and ended up enrolling 256 patients....so there can't have been too much of a responder overload. Obviously, those who remain in the trial after 5-6 months are by definition responders, but that is true in any trial of rGBM patients by definition considering the median overall survival.

The interesting post-hoc analysis might be comparing patients who received checkpoint inhibitors and VB-111 compared to those who did not.

[Prana1]

What gives me the reassurance is that the principal investigator is in the USA.
2) the trial was completed a solid 5 months ahead of schedule. That's a bit impressive- that means it must have been a favorite among the various other investigators handling the trial at various centers.
What I mean by that is that for a particular cancer these guys have quite a few options to plug pts in different trials but they seem to have sent them down this trial. That's a bit of confidence on the doctors part. That's reassuring to me.
3) as soon as they announced that the trial was complete they also announce that they made some changes to the trial structure.
(Under normal circumstances that's a big red hot flag for me and I yank out my investment)
But I haven't had the time to assess what they changed.
That's my work for this weekend.
( if anyone has seen the changes or has comments about them would love to hear about their DD)
Always hoping for the best for pts.

It's time for GBM to be shut out.
Let see.